Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agenus, ChemRar strike cancer vaccines deal
Under the terms of the deal, Agenus has granted NewVac an exclusive license to manufacture, market and sell Oncophage as well as pursue a development program of Oncophage
Under the terms of the deal, Agenus has granted NewVac an exclusive license to manufacture, market and sell Oncophage as well as pursue a development program of Oncophage
According to the researchers, low-cost artemisinin-based drugs are lacking because of the high cost of obtaining the natural or chemically synthesized drug. Owing to tobacco’s high biomass and
The agreement covers granting Kinex Pharmaceuticals exclusive rights to Hanmi’s Orascovery technology and products including an oral formulation of paclitaxel and an oral formulation of irinotecan. Orascovery technology
SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins. The placebo-controlled, double-blind, ascending single dose
IPX159 is an oral controlled-release formulation of a small molecule that has an established pharmacological and safety profile for non-RLS use outside the US. The multicenter, randomized, double-blind,
Aviir’s TruRisk technology consists of a blood test that measures the blood levels of 7 proteins associated with the development of unstable plaque. It then uses a complex
Exparel combines bupivacaine with DepoFoam, a proven product delivery technology that delivers bupivacaine for an extended period of time, providing analgesia with reduced opioid requirements for up to
The two Novato facilities are said to support up to $1bn in revenue for BioMarin’s growing enzyme replacement therapy portfolio. BioMarin CEO Jean-Jacques Bienaime said the company is
According to the company, the one-year Target Validation Funding Award will support pathway validation experiments to show the efficacy of novel biased ligands to the delta-opioid receptor in
According to both the companies commercialization of biosimilar products will not follow a pure brand or generic model. As per the collaboration, Amgen will take up developing, manufacturing